Shenzhen-based Chinese gene sequencing giant BGI Genomics Co., Ltd is making another try for a listing on the ChiNext board of the Shenzhen Stock Exchange, seeking to raise US$250 million by issuing 40 million new shares, after its previous application was rejected last November.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
